Related by context. All words. (Click for frequent words.) 79 adjuvant therapy 75 neoadjuvant chemotherapy 74 chemoradiation 72 neoadjuvant 71 adjuvant radiotherapy 71 adjuvant radiation 71 preoperative chemotherapy 70 neoadjuvant therapy 68 trastuzumab 68 curative resection 68 chemoradiotherapy 68 lymphadenectomy 68 bevacizumab 67 FOLFOX4 67 gemcitabine 67 cetuximab 67 postoperative chemotherapy 67 XELOX 67 EBRT 67 biochemical recurrence 66 antiplatelet therapy 66 breast conserving 66 neoadjuvant treatment 66 Adjuvant chemotherapy 66 clinically localized prostate 66 FOLFOX 66 metastatic RCC 65 ALND 65 postoperative radiotherapy 65 lymph node dissection 65 Doxil ® 65 HER2 positive metastatic breast 65 sentinel lymph node biopsy 65 stage IIIB 65 bevacizumab Avastin 65 hormonal therapy 65 FDG PET 65 locoregional recurrence 65 distant metastases 65 locoregional 65 axillary dissection 65 tumor recurrence 65 IV NSCLC 65 adjuvant therapies 65 resectable 65 KRAS mutation 65 fluorouracil 64 pegylated interferon alfa 2b 64 androgen deprivation 64 cystectomy 64 tamoxifen therapy 64 pemetrexed 64 external beam radiotherapy 64 HER2 negative 64 chemoradiation therapy 64 debulking surgery 64 lymph node metastases 64 NSCLC 64 brain metastases 64 gefitinib 64 5-FU/LV 64 docetaxel 64 chemotherapy regimens 64 carboplatin paclitaxel 63 lymph node involvement 63 operable breast cancer 63 platinum refractory 63 Neoadjuvant 63 pCR 63 5FU 63 radical nephrectomy 63 localized prostate cancer 63 GnRH agonists 63 nab paclitaxel 63 dasatinib 63 mycophenolate mofetil 63 cisplatin 63 cytoreductive surgery 63 FOLFIRI 63 medically inoperable 63 sentinel node biopsy 63 EGFR mutations 63 epithelial ovarian cancer 63 vandetanib 63 adjuvant tamoxifen 63 PSADT 63 SLNB 63 anthracyclines 63 radical prostatectomy 63 lipid lowering therapy 63 micrometastases 62 cytotoxic chemotherapy 62 metastatic renal cell carcinoma 62 pneumonectomy 62 temsirolimus 62 Taxotere ® 62 EUS FNA 62 liver metastases 62 letrozole 62 completely resected 62 unresectable 62 chemotherapy regimen 62 tamoxifen 62 taxane therapy 62 DMARD 62 erlotinib 62 allogeneic SCT 62 mCRC patients 62 statin therapy 62 ICD implantation 62 anastrozole 62 prostate biopsy 62 advanced adenomas 62 fondaparinux 62 capecitabine 62 surgical debulking 62 carboplatin 62 temozolomide 62 KRAS mutations 62 histologically confirmed 62 dacarbazine 62 squamous histology 62 sunitinib 62 prostate cancer CRPC 61 relapsed ovarian cancer 61 pegylated liposomal doxorubicin 61 metastatic castration resistant 61 docetaxel chemotherapy 61 breast carcinoma 61 axillary lymph node dissection 61 distant metastasis 61 chlorambucil 61 bortezomib 61 underwent resection 61 KRAS status 61 pertuzumab 61 standard chemotherapy regimens 61 pT2 61 prognostic factors 61 epirubicin 61 hepatic metastases 61 androgen suppression 61 colorectal liver metastases 61 subgroup analyzes 61 PCa 61 cisplatin chemotherapy 61 androgen ablation 61 sorafenib Nexavar 61 axillary nodes 61 stage IIIb IV 61 resected 61 chemotherapeutic regimens 61 pelvic lymphadenectomy 61 gemcitabine chemotherapy 61 nonmetastatic 61 median PFS 61 relapsed SCLC 61 Recurrence Score 60 dose cytarabine 60 advanced NSCLC 60 radical cystectomy 60 cytoreductive nephrectomy 60 zoledronic acid 60 standard chemotherapy regimen 60 contralateral breast cancer 60 Subgroup analyzes 60 recurrent NSCLC 60 malignant pleural mesothelioma 60 HGPIN 60 sorafenib 60 axillary lymph nodes 60 ABVD 60 adjuvant hormonal therapy 60 vinorelbine 60 differentiated thyroid 60 tumor resection 60 pancreatic adenocarcinoma 60 mRCC 60 endometrial carcinoma 60 Trastuzumab 60 glycoprotein IIb IIIa inhibitors 60 preoperative radiotherapy 60 Torisel 60 allogeneic stem cell 60 randomized trials 60 recurrent GBM 60 metastatic HRPC 60 gemcitabine Gemzar 60 APTIVUS r 60 free survival PFS 60 intravenous bisphosphonates 60 BRCA mutation carriers 60 antibiotic prophylaxis 60 trabectedin 60 invasive carcinoma 60 sipuleucel T 60 mitoxantrone 60 clopidogrel 60 adjuvant endocrine therapy 60 axillary node dissection 60 contralateral breast 60 heavily pretreated 60 Folfox 60 estrogen receptor negative 60 adverse cytogenetics 60 Adjuvant therapy 60 warfarin therapy 60 recurrent VTE 59 F FDG PET 59 chemoembolization 59 olaparib 59 heavily pretreated patients 59 adenomatous polyps 59 radical prostatectomy RP 59 NATRECOR R 59 mediastinoscopy 59 Surgical resection 59 eribulin 59 hormone receptor negative 59 abciximab 59 estrogen receptor positive 59 neoplasia 59 virologic failure 59 partial nephrectomy 59 iniparib 59 HSCT 59 Median survival 59 DMARDs 59 TORISEL 59 prostate cancer CaP 59 HER2 positive breast cancer 59 metastatic disease 59 endarterectomy 59 antithrombotic therapy 59 cytoreduction 59 imatinib 59 paclitaxel carboplatin 59 salpingo oophorectomy 59 prognostic variables 59 Lenalidomide 59 imatinib therapy 59 fludarabine 59 rFVIIa 59 gemcitabine carboplatin 59 TACE 59 pre menopausal 59 non squamous NSCLC 59 recurrent glioblastoma multiforme 59 Kaplan Meier analysis 59 BRCA2 mutation carriers 59 folinic acid 59 esophagectomy 59 BEACOPP 59 MGd 59 idarubicin 59 peginterferon 59 hormone receptor positive 59 5 fluorouracil 59 virologic response 59 radiotherapy RT 59 castration resistant prostate cancer 59 nodal metastases 59 colectomy 59 Zevalin consolidation 59 WBRT 59 chemotherapy docetaxel 59 CMV disease 59 HER2 positive 59 oophorectomy 59 tumor histology 59 Free Survival PFS 59 recurrent prostate cancer 59 follicular NHL 59 axillary lymph node 59 thyroid nodules 59 carotid endarterectomy 59 androgen deprivation therapy 59 bevacizumab Avastin ® 59 beta blocker therapy 59 Herceptin trastuzumab 59 irinotecan chemotherapy 59 renal tumors 59 advanced adenoma 59 ixabepilone 59 anthracycline containing 59 low dose cytarabine 59 advanced neoplasia 59 EGFR TKI 59 gefitinib Iressa 59 screening mammography 59 azathioprine 59 iniparib BSI 59 prostatectomy 59 orchiectomy 59 tumor shrinkage 59 adenotonsillectomy 59 estramustine 59 dose dexamethasone 59 biochemical relapse 58 paclitaxel eluting stents 58 cytotoxic therapy 58 DAPT 58 neoadjuvant chemoradiotherapy 58 radioiodine therapy 58 resection 58 CR nPR 58 comorbidities 58 oral Xeloda 58 Radical prostatectomy 58 placebo dexamethasone 58 Flu Cy 58 plus dexamethasone 58 FDG-PET/CT 58 adenoma recurrence 58 HNSCC 58 5-fluorouracil/leucovorin 58 liver transplant recipients 58 undergoing radical prostatectomy 58 interferon alfa 58 endosonography 58 testosterone supplementation 58 Taxotere 58 remission induction 58 fibrinolytic therapy 58 tirofiban 58 azacitidine 58 decitabine 58 OPAXIO 58 endocrine therapy 58 dual antiplatelet therapy 58 DOXIL 58 GP IIb IIIa inhibitors 58 doxorubicin docetaxel 58 lymph node metastasis 58 patients undergoing CABG 58 breast cancer recurrence 58 exemestane 58 lobectomy 58 pT3 58 FOLFIRI alone 58 neoadjuvant radiation 58 daunorubicin 58 liver metastasis 58 CCyR 58 IIIA NSCLC 58 Accelerated Partial Breast Irradiation 58 anthracycline therapy 58 alteplase 58 virologic responses 58 unfractionated heparin 58 sentinel node 58 bendamustine 58 5 FU 58 coinfected patients 58 mg/m2 dose 58 dacarbazine chemotherapy 58 definite stent thrombosis 58 oral clodronate 58 pazopanib 58 nephron sparing surgery 58 metastatic malignant melanoma 58 dacarbazine DTIC 58 rosuvastatin 58 figitumumab 58 Bevacizumab 58 FOLFIRINOX 58 metastatic breast cancer 58 adenoma 58 cabazitaxel 58 atypical hyperplasia 58 antiangiogenic therapy 58 stage IIIB IV 58 mammographic density 58 K ras mutations 58 rituximab 58 radiochemotherapy 58 eptifibatide 58 univariate analysis 58 Erlotinib 58 β blockers 58 BCIRG 58 invasive lobular carcinoma 58 antihypertensive therapy 58 oxaliplatin 58 topotecan 58 paclitaxel cisplatin 58 prognostic factor 57 TNF blocker therapy 57 unresectable stage 57 CaP 57 flutamide 57 metastatic colorectal cancer 57 bilateral oophorectomy 57 Bortezomib 57 prostate carcinoma 57 HER2 + 57 abiraterone acetate 57 R0 resection 57 recurrent ovarian cancer 57 endometrial hyperplasia 57 revascularization 57 occult metastases 57 elective PCI 57 lenalidomide 57 Subgroup analysis 57 GnRH agonist 57 grade cervical intraepithelial 57 intraperitoneal chemotherapy 57 perioperatively 57 ELOXATIN 57 liver resection 57 androgen independent 57 Gemcitabine 57 goserelin 57 evaluable 57 FOLFOX6 57 adriamycin 57 Tamoxifen 57 EGFR mutation positive 57 methotrexate monotherapy 57 lipid lowering drugs 57 ovarian carcinoma 57 nephrectomy 57 Combination therapy 57 cranial radiation 57 riociguat 57 fluoropyrimidine 57 perioperative morbidity 57 anthracycline 57 nodal dissection 57 LV dysfunction 57 intravesical therapy 57 tocilizumab 57 postoperative mortality 57 letrozole Femara 57 IV melanoma 57 Natalizumab 57 cancer mCRC 57 EGFR mutation 57 methotrexate therapy 57 NCCTG N# 57 EGFR inhibitors 57 cisplatin vinorelbine 57 afatinib 57 SLN biopsy 57 PNH patients 57 clopidogrel pretreatment 57 mildly symptomatic 57 STRIDE PD 57 cytogenetic response 57 erlotinib Tarceva ® 57 progression TTP 57 posaconazole 57 PegIFN RBV 57 hepatocellular carcinoma 57 interferon therapy 57 Pemetrexed 57 Irinotecan 57 hepatocellular carcinomas 57 surrogate endpoint 57 VcMP 57 eplerenone 57 fine needle aspiration 57 metachronous 57 leucovorin 57 lapatinib 57 aromatase inhibitor 57 thrombolytic therapy 57 lymph node removal 57 coronary revascularization 57 anthracycline taxane 57 resistant ovarian cancer 57 Platinol ® cisplatin 57 CsA 57 seminoma 57 revascularization procedures 57 NSABP B 57 bladder carcinoma 57 febrile neutropenia 57 Percutaneous Coronary Intervention 57 thromboprophylaxis 57 asymptomatic carotid stenosis 57 metastatic malignant 57 infusional 5-FU/LV 57 sustained virologic response 57 screening colonoscopy 57 DMARD therapy 57 adjuvant trastuzumab 57 platelet reactivity 57 perioperative mortality 57 weekly subcutaneous injections 57 MACCE 57 ErbB2 positive 57 MetS 57 chemotherapy 57 receptor tyrosine kinase inhibitor 57 hepatectomy 57 HER2 positive cancers 57 trastuzumab Herceptin 57 hepatic resection 57 everolimus eluting stents 57 lumpectomy 57 graft occlusion 57 cilostazol 57 relapsed ALL 57 bone metastasis 57 multivariate analyzes 57 FOLPI 56 undergone radical prostatectomy 56 CABG 56 cyclophosphamide 56 hematologic toxicity 56 pioglitazone 56 underwent surgical resection 56 nonsmall cell lung cancer 56 cyclophosphamide methotrexate 56 NSTE ACS 56 dutasteride 56 aspirin clopidogrel 56 parathyroidectomy 56 prednisone prednisolone 56 fallopian tube carcinoma 56 adalimumab 56 irinotecan 56 clodronate 56 EGFR TKIs 56 randomized controlled trials 56 tumor lysis syndrome 56 Platinol ® 56 CYPHER Stent 56 endothelin antagonists 56 surgical resection 56 metastatic lung cancer 56 oblimersen 56 docetaxel Taxotere 56 nonrandomized 56 liposomal amphotericin B 56 Fludara 56 custirsen 56 thromboembolic events 56 concurrent chemoradiation 56 endocrine therapies 56 asymptomatic metastatic 56 plus prednisone 56 TTF Therapy 56 prophylactic cranial irradiation 56 serum PSA 56 low dose dexamethasone 56 Response Evaluation Criteria 56 vitamin D supplementation 56 sleeve lobectomy 56 hormone refractory 56 melphalan prednisone 56 fluvastatin 56 cisplatin gemcitabine 56 mitomycin C 56 antidepressant therapy 56 cediranib 56 contralateral prophylactic mastectomy 56 untreated AML 56 refractory AML 56 metastatic prostate cancer 56 T1c 56 KRAS mutations occur 56 Thal Dex 56 prospectively defined 56 #F FDG PET 56 pomalidomide 56 Velcade bortezomib 56 antimicrobial prophylaxis 56 baseline LDH 56 CHOP chemotherapy 56 severe neutropenia 56 metastatic GIST 56 5 Fluorouracil 56 ICD therapy 56 MAGE A3 ASCI 56 perioperative complications 56 prophylactic mastectomy 56 transurethral resection 56 tamoxifen Nolvadex ® 56 thromboembolic 56 oral Hycamtin 56 colorectal cancer liver metastases 56 VTE prophylaxis 56 sunitinib malate 56 PLCO 56 Temsirolimus 56 breast conserving lumpectomy 56 NovoTTF 56 elacytarabine 56 virological response 56 Capecitabine 56 doxorubicin 56 Cisplatin 56 optical colonoscopy 56 premenopausal 56 RECIST Response Evaluation Criteria 56 overlapping toxicities 56 liposomal doxorubicin 56 TOP2A 56 prostate cancer AIPC 56 comorbidity 56 PSA screening 56 cranial irradiation 56 conventional angiography 56 BENICAR HCT 56 periprocedural 56 dose clopidogrel 56 endometrial cancers 56 oral anticoagulation 56 capecitabine Xeloda 56 tyrosine kinase inhibitors 56 postmenopausal hormone therapy 56 situ LCIS 56 reperfusion therapy 56 histologic 56 Elitek 56 Paraplatin ® 56 docetaxel prednisone 56 renal dysfunction 56 remission CR 56 RTOG 56 trastuzumab Herceptin ® 56 axitinib 56 ATACAND 56 galiximab 56 urothelial carcinoma 56 EGFR mutation status 56 Bezielle 56 aromatase inhibitors AIs 56 Platinol 56 imatinib Gleevec 56 Metastatic Prostate Cancer 56 ACUITY trial 56 FOLFOX regimen 56 Gefitinib 56 radiation therapy 56 antiviral therapy 56 HRPC 56 HIPEC 56 palifermin 56 axillary node 56 CR# vcMMAE 56 dosage regimens 56 repeat revascularization 56 Pegasys plus Copegus 56 placebo controlled trials 56 T1a 56 ipsilateral breast 56 aromatase inhibitor therapy 56 cervical carcinoma 56 EFAPROXYN 56 insulin detemir 56 PSA velocity 56 polyp recurrence 56 therapeutic regimens 56 H. pylori eradication 55 malignant lesions 55 adecatumumab 55 acute myelogenous leukemia AML 55 octreotide LAR 55 neurologic progression 55 undergone hysterectomy 55 paclitaxel Taxol 55 medullary thyroid cancer 55 sustained virological response 55 AVODART 55 resected pancreatic cancer 55 diagnosed multiple myeloma 55 comorbid conditions 55 achieved ACR# 55 chemoprevention 55 LVEF 55 plus gemcitabine 55 superficial bladder cancer 55 unresectable tumors 55 sirolimus eluting stents 55 aldosterone antagonists 55 androgen suppression therapy 55 complete remissions 55 risk stratification 55 STEMI patients 55 metastases 55 chronic lymphocytic leukemia CLL 55 coronary angiography 55 DES implantation 55 gastric cancer 55 RECIST criteria 55 HER2 positive tumors 55 Cristofanilli 55 BRCA1 mutation carriers 55 nodal metastasis 55 mapatumumab 55 tesmilifene 55 KRAS mutant tumors 55 infusional 55 relapsing multiple sclerosis 55 Cetuximab 55 localized renal 55 mitoxantrone chemotherapy 55 colorectal cancer 55 Hazard Ratio 55 BRCA2 mutations 55 taxane chemotherapy 55 peritoneal carcinomatosis 55 Pertuzumab 55 Halaven 55 bone scintigraphy 55 etoposide 55 taxane 55 nonfatal MI 55 elevated CRP 55 excisional biopsy 55 chemotherapeutic agents 55 adjuvant 55 metastatic CRPC 55 hepatocellular carcinoma HCC 55 ALLHAT 55 HYVET 55 dalteparin 55 concomitant medications 55 univariate 55 grade gliomas 55 ER CHOP 55 evaluable patients 55 metastatic lesions 55 papillary renal cell carcinoma 55 intraperitoneal therapy 55 Mylotarg 55 Adjuvant Therapy 55 erlotinib Tarceva 55 ribavirin RBV 55 IFN alfa 55 Solid Tumors 55 invasive coronary angiography 55 epithelial tumors 55 prognostic 55 colorectal neoplasia 55 hormone receptor status 55 urothelial bladder cancer 55 chemotherapy cisplatin 55 iodixanol 55 HER2 overexpression 55 hormone therapy estrogen 55 Exemestane 55 Metastatic 55 cetuximab Erbitux 55 breast cancer subtypes 55 EURIDIS 55 HBeAg positive patients 55 multicenter randomized controlled 55 SWOG 55 anticoagulant therapy 55 recurrent ovarian 55 genotypic resistance 55 postmenopausal osteoporotic women 55 thyroidectomy 55 complete cytogenetic 55 D dimer 55 urine cytology 55 Hematologic 55 PXD# 55 PREZISTA r 55 prostate cancer PCa 55 bosentan 55 lenalidomide dexamethasone 55 ASCT 55 Ranolazine 55 Solid Tumors RECIST 55 RECIST 55 mucosal healing 55 sunitinib Sutent 55 interferon alfa 2b 55 NATRECOR ® 55 BRAF mutation 55 stavudine d4T 55 prostate cancer HRPC 55 anti leukemic 55 Stage IIIb 55 Revlimid lenalidomide 55 relapsed MM 55 histological subtype 55 uric acid lowering 55 radiation therapy SBRT 55 nonresponders 55 PSA nadir 55 leukemia AML 55 antiplatelet drugs 55 PROSTVAC TM 55 Cloretazine 55 premenopausal women 55 HCV SPRINT 55 HCV infected 55 underwent radical prostatectomy 55 LHRH agonists 55 tibolone 55 d4T 55 VIDAZA 55 T DM1 55 multicentre randomized 55 nilotinib 55 bivalirudin 55 multimodality therapy 55 dexamethasone Decadron 55 antioxidant supplementation 55 antigen PSA 55 TroVax ® 55 metastatic kidney 55 lobular carcinoma 55 pamidronate 55 tumor necrosis 55 nonoperative treatment 55 chemo radiotherapy 55 rt PA 55 radiotherapy SBRT 55 undetectable HBV DNA 55 ribavirin therapy 55 MADIT II 55 CLL SLL 55 urothelial cancer 55 total thyroidectomy 55 octreotide 55 metastatic hormone refractory 55 preoperative 55 SBRT 55 prognostic biomarker 55 melphalan 55 sigmoidoscopy 55 Follicular Lymphoma 55 gp# vaccine 55 paricalcitol 55 glatiramer acetate 55 core needle biopsy 55 prior chemotherapy regimens 55 cardiac toxicity 55 IIIa inhibitor 55 enzastaurin 55 unfavorable prognostic 55 fulvestrant 55 antiretroviral naïve 55 PEGylated interferon beta 1a 55 CANCIDAS 55 sarcomatoid 55 allogeneic transplant 55 carotid endarterectomy CEA 55 thoracoscopic lobectomy 55 invasive breast cancer 55 FOLFOX chemotherapy 55 atypia 55 ACC AHA 55 curative therapy 55 oral ridaforolimus 55 histologies 55 abatacept 55 complete cytogenetic response 55 viral kinetics 55 partial remissions 55 subclinical hypothyroidism 55 thrombocytopenic 55 irbesartan 55 glufosfamide 55 metastatic gastric 55 TEMODAL 55 HeFT 55 gastrointestinal stromal tumors 55 palliation 55 basal cell carcinoma BCC 55 APTIVUS ritonavir 55 alkylating agents 55 bevacizumab Avastin Genentech 55 postmenopausal women 55 disease progression 55 stent implantation 55 subtrochanteric 55 minimally symptomatic 55 trastuzumab DM1 55 Femara letrozole 55 randomized multicenter trial 55 metastatic bladder 55 precursor lesions 55 advanced epithelial ovarian 55 hormone refractory metastatic prostate 55 peg IFN 55 extracapsular extension 55 clinicopathological features 55 BRCA1 mutations 55 undergoing CABG 55 idraparinux 54 beam radiotherapy 54 NMIBC 54 teriflunomide 54 stereotactic radiotherapy 54 paclitaxel 54 ACCORD Lipid 54 aldosterone antagonist 54 androgen deficiency 54 antitumor effect 54 vertebral fracture 54 metastatic renal cell 54 insulin glargine 54 renal cell carcinomas 54 colorectal adenoma 54 EORTC 54 Peginterferon 54 splenectomized patients 54 unstable angina UA 54 oral antidiabetic medication 54 coronary stenting 54 de novo AML 54 dose escalation 54 carotid artery stenting 54 IRESSA 54 Adjuvant 54 docetaxel Taxotere ® 54 chemoresistant 54 assessing T DM1 54 ABCSG 54 fallopian tube cancers 54 TAXUS Liberte Stent 54 paclitaxel Taxol R 54 duplex ultrasonography 54 T2DM 54 TNF inhibitor 54 Sunitinib 54 tamsulosin 54 Oncotype DX Recurrence Score 54 receiving highly emetogenic 54 cirrhotic patients 54 metastatic castrate resistant 54 diffuse gastric 54 SCCHN 54 estrogen receptor ER 54 immunosuppressive agents 54 vicriviroc 54 FDG PET imaging 54 Xelox 54 aromatase inhibitors 54 cinacalcet 54 patients evaluable 54 EXJADE 54 breast irradiation 54 composite endpoint 54 R# #mg BID 54 ERCC1 54 ipsilateral stroke 54 serous ovarian cancer 54 Allovectin 7 ® 54 postoperative complication 54 epithelial ovarian 54 enfuvirtide 54 Gemzar ® 54 ELACYT 54 hydroxychloroquine 54 specific antigen PSA 54 febuxostat 54 mg kg dose 54 NRTIs 54 trials RCTs 54 Adjuvant Chemotherapy 54 adenomas 54 lintuzumab 54 treatment regimens 54 Median progression 54 ACTEMRA TM 54 undergoing coronary angiography 54 KRAS wild 54 adjuvant cisplatin 54 chemotherapeutic agent 54 substudy 54 venous thromboembolism 54 stage IIIA 54 prospectively randomized 54 LEXIVA r 54 oral FTY# 54 metastatic CRC 54 recurrent metastatic 54 BRIM2 54 selenium supplementation 54 coronary intervention 54 symptomatic VTE 54 Ceplene/IL-2 54 abiraterone 54 nesiritide 54 N acetylcysteine 54 thienopyridine 54 Fulvestrant 54 strontium ranelate 54 oncologic outcomes 54 hormone refractory prostate cancer 54 node metastases 54 HAART regimens 54 randomized clinical trials 54 bone metastases 54 hormone therapy 54 panobinostat 54 pregabalin 54 alkylating agent 54 ß blockers